Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

Stock Information for 5E Advanced Materials Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About 5E Advanced Materials Inc.

Arcturus Therapeutics to Attend Upcoming Investor Conference
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm
Arcturus Therapeutics to Attend Upcoming Investor Conferences
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
Arcturus Therapeutics to Attend Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.